Skip to content

Robotic Arm Intervention for Stroke rEcovery (RAISE): A pilot randomised controlled trial

Robotic Arm Intervention for Stroke rEcovery (RAISE): A pilot randomised controlled trial evaluating the efficacy of a novel exoskeleton device for improving upper limb impairment post stroke

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12625000378426
Acronym
RAISE
Enrollment
0
Registered
2025-04-29
Start date
2025-07-28
Completion date
2026-06-30
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This pilot feasibility study will assess delivery of high dose motor retraining through the use of a novel exoskeleton device. The use of robotic technologies can improve upper limb outcomes post stroke, providing stroke survivors with repetitive and task-specific motor retraining. Additionally, robotic technologies can provide opportunities for active practice for stroke survivors with severe upper limb weakness and provide immediate feedback to stroke survivors and clinicians on motor performance, supporting engagement in therapy and providing opportunities to personalise intervention. This study will also provide information on the feasibility and acceptability of the use of this particular technology, which will be used to inform a larger, fully powered clinical trial.

Interventions

Participants in the intervention group will receive a minimum of 40 hours additional therapy delivered five days per week (Mon-Fri) over four weeks, equating to approximately two hours per day. This therapy will be comprised of task specific motor training (75mins) and robotic therapy (45mins) delivered by a trained occupational therapist or physiotherapist. Task specific motor training will be delivered using a specifically developed manual, tailored to the individual's abilities. Activities wi

Participants in the intervention group will receive a minimum of 40 hours additional therapy delivered five days per week (Mon-Fri) over four weeks, equating to approximately two hours per day. This therapy will be comprised of task specific motor training (75mins) and robotic therapy (45mins) delivered by a trained occupational therapist or physiotherapist. Task specific motor training will be delivered using a specifically developed manual, tailored to the individual's abilities. Activities will include tasks such as reaching for a cup to practice shoulder forward flexion and external rotation or attaching pegs to a line to practice train finger dexterity. Each activity within the manual has pre-planned levels of difficulty and modifications that may be enacted in order to individualise the activity to the participants ability. Robotic therapy will be delivered using a portable robotic exoskeleton with real time visual biofeedback and electromyography (EMG) activation (see doi: 10.1186/s12984-021-00867-7). The device is comprised of a forearm and hand support and simple visual display. Participants will be asked to attempt to extend their wrist and fingers. The EMG sensor will register muscle activity as the person attempts the movement, activating the device and moving the hand into wrist and finger extension. Intervention will primarily be delivered within a clinical setting, with the option for intervention delivery in the participant's home or via telehealth as required at the discretion of the site investigator. In clinical settings, therapy may be delivered using a combination of individual and semi-supervised sessions (with up to three participants: 1 therapist). Program adherence data will be collected by recording the duration of sessions (time spent active vs inactive), level of difficulty of therapy tasks (as reported by participants) and amount of repetitions completed. Acceptability of the high dose motor retraining program will be measured via i) the theoretical framework of acceptability (TFA) questionnaire, which consists of seven component constructs of acceptability of an intervention and an overall acceptability measure and ii) The 10 question System Usability Scale (SUS), a validated tool, which measures a users’ experience of technology. This data will be collected by members of the research team.

Sponsors

St Vincent's Health Network Sydney Limited
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

First diagnosis of stroke, confirmed by neuroimaging Aged 18 years or over Eligible for Transcranial Magnetic Stimulation (TMS) Moderate to severe upper limb impairment as indicated by a Shoulder Abduction Finger Extension (SAFE) score of 2-7 Pre-morbid modified Rankin score of 3 or less > 7 days and < 3 months post stroke onset Short Portable Mental Status Questionnaire (SPMSQ) of > 5

Exclusion criteria

People with contraindicators to magnetic resonance imaging (MRI) People with absolute contraindicators to Transcranial Magnetic Stimulation (TMS) Diagnosis of cerebellar stroke Pre-morbid modified Rankin score of 4 or greater Extremely severe upper limb impairment (SAFE score >7) Mild upper limb impairment (SAFE score <2) Short portable mental status questionnaire (SPMSQ) score of higher than 5 Unable to give informed consent

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026